- Companies
- Nanjing Pharmaceutical
Nanjing Pharmaceutical Valuation Multiples
Nanjing Pharmaceutical is valued at $964M as of September 2026, a 0.3x revenue multiple. In the last fiscal year, Nanjing Pharmaceutical revenue was $8.2B and Nanjing Pharmaceutical EBITDA was $257M.
Nanjing Pharmaceutical Overview
About Nanjing Pharmaceutical
Nanjing Pharmaceutical is a Chinese pharmaceutical distribution and retail group whose operating history dates to 1951. Listed on the Shanghai Stock Exchange since 1996, it supplies medicines and healthcare products to medical institutions and serves consumers through pharmacy chains. Its core business combines pharmaceutical wholesaling with retail pharmacy sales, supported by regional warehousing, delivery and supply-chain services. The company also distributes medical devices and provides specialized pharmacy services, including preparation and delivery of traditional Chinese medicine products. Its corporate overview describes a network covering Jiangsu, Anhui, Fujian and Hubei, together with operations in Kunming and other regional markets. For 2025, it reported approximately 500 retail pharmacies and 49 logistics centers, illustrating the physical distribution infrastructure through which it connects suppliers, healthcare providers and patients.
Founded
1951
HQ
Employees
7.2K
Website
Financials (Last FY)
EV
$2.1B
Valuation Multiples
Start free trialNanjing Pharmaceutical Financials
Nanjing Pharmaceutical reported last fiscal year revenue of $8.2B and EBITDA of $257M.
In the same fiscal year, Nanjing Pharmaceutical generated $505M in gross profit, $257M in EBITDA, and $93M in net income.
Nanjing Pharmaceutical P&L
In the most recent fiscal year, Nanjing Pharmaceutical reported revenue of $8.2B and EBITDA of $257M.
Nanjing Pharmaceutical is profitable as of last fiscal year, with gross margin of 6%, EBITDA margin of 3%, and net margin of 1%.
Financial data powered by Morningstar, Inc.
Nanjing Pharmaceutical Stock Performance
Nanjing Pharmaceutical has current market cap of $964M, and enterprise value of $2.1B.
Market Cap Evolution
Nanjing Pharmaceutical's stock price is $0.74.
Nanjing Pharmaceutical has an EPS (earnings per share) of $0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $964M | 0.3% | - | - | - | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanjing Pharmaceutical Valuation Multiples
Nanjing Pharmaceutical trades at 0.3x EV/Revenue multiple, and 8.2x EV/EBITDA.
Nanjing Pharmaceutical Financial Valuation Multiples
As of September 30, 2026, Nanjing Pharmaceutical has market cap of $964M and EV of $2.1B.
Nanjing Pharmaceutical has a P/E ratio of 10.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanjing Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nanjing Pharmaceutical Margins & Growth Rates
In the most recent fiscal year, Nanjing Pharmaceutical reported gross margin of 6%, EBITDA margin of 3%, and net margin of 1%.
Nanjing Pharmaceutical Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanjing Pharmaceutical Operational KPIs
Nanjing Pharmaceutical's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanjing Pharmaceutical Competitors
Nanjing Pharmaceutical competitors include Quest Holdings, Yixintang Pharmaceutical, Almunajem Foods, Apotea, Anhui Huaren Health, Hagar, Shu Yu Civilian Pharmacy, Chang Wah Electromaterials, Neuca and Aldawaa Medical Services.
Most Nanjing Pharmaceutical public comparables operate across Wholesale Distribution and Pharmacies.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.7B | $111M | 0.6x | 0.6x | 8.7x | 8.5x | |||
| $2.6B | $264M | 0.3x | 0.3x | 3.0x | 6.0x | |||
| $891M | $65M | 1.2x | 1.2x | 16.1x | 18.3x | |||
| $723M | $46M | 1.3x | 1.2x | 20.1x | 16.2x | |||
| $818M | $97M | 1.2x | - | 9.9x | - | |||
| $1.6B | $157M | 0.9x | - | 9.1x | - | |||
| $1.5B | $105M | 0.7x | 0.8x | 10.8x | 11.8x | |||
| $608M | $79M | 1.5x | - | 11.3x | - | |||
This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical competitors and their valuation data. Start Free Trial | ||||||||
Nanjing Pharmaceutical VC Funding History
Before going public, Nanjing Pharmaceutical raised $89M in total equity funding, across 1 round.
Nanjing Pharmaceutical Funding Rounds
Acquisitions by Nanjing Pharmaceutical
Nanjing Pharmaceutical has acquired 1 company to date.
Last acquisition by Nanjing Pharmaceutical was on December 20th 2022. Nanjing Pharmaceutical acquired Suzhou Tianqing Xingwei Pharmaceutical for undisclosed valuation.
Latest Acquisitions by Nanjing Pharmaceutical
| Description | Suzhou Tianqing Xingwei Pharmaceutical is a research and development firm focused on liver disease treatments. The company develops innovative drugs targeting hepatitis and related conditions, conducting clinical trials and securing approvals from China's National Medical Products Administration. Suzhou-based, it collaborates with hospitals across Jiangsu province for patient data and testing. |
| HQ Country | |
| HQ City | Suzhou |
| Deal Date | 20 Dec 2022 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Nanjing Pharmaceutical
Nanjing Pharmaceutical has invested in 1 company to date.
Latest investment by Nanjing Pharmaceutical was on February 27th 2018. Nanjing Pharmaceutical invested in WANHU HEALTH in their $500K Pre-seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Nanjing Pharmaceutical
| Description | WANHU HEALTH is a health services provider specializing in disease prevention and critical illness insurance for groups. It delivers risk profiling, supplementary serious illness coverage, and early screening programs to mitigate family medical costs via wanhuhealth.com. |
| HQ Country | |
| HQ City | Beijing |
| Deal Date | 27 Feb 2018 |
| Round | Pre-seed |
| Raised | $500K |
| Investors | Nanjing Pharmaceutical |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Nanjing Pharmaceutical investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanjing Pharmaceutical
| When was Nanjing Pharmaceutical founded? | Nanjing Pharmaceutical was founded in 1951. |
| Where is Nanjing Pharmaceutical headquartered? | Nanjing Pharmaceutical is headquartered in China. |
| How many employees does Nanjing Pharmaceutical have? | As of today, Nanjing Pharmaceutical has over 7K employees. |
| Is Nanjing Pharmaceutical publicly listed? | Yes, Nanjing Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Nanjing Pharmaceutical? | Nanjing Pharmaceutical trades under 600713 ticker. |
| When did Nanjing Pharmaceutical go public? | Nanjing Pharmaceutical went public in 1996. |
| Who are competitors of Nanjing Pharmaceutical? | Nanjing Pharmaceutical main competitors include Quest Holdings, Yixintang Pharmaceutical, Almunajem Foods, Apotea, Anhui Huaren Health, Hagar, Shu Yu Civilian Pharmacy, Chang Wah Electromaterials, Neuca, Aldawaa Medical Services. |
| What is the current market cap of Nanjing Pharmaceutical? | Nanjing Pharmaceutical's current market cap is $964M. |
| What is the current revenue of Nanjing Pharmaceutical? | Nanjing Pharmaceutical's last fiscal year revenue is $8.2B. |
| What is the current EV/Revenue multiple of Nanjing Pharmaceutical? | Current revenue multiple of Nanjing Pharmaceutical is 0.3x. |
| Is Nanjing Pharmaceutical profitable? | No, Nanjing Pharmaceutical is not profitable. |
| How many companies Nanjing Pharmaceutical has acquired to date? | As of September 2026, Nanjing Pharmaceutical has acquired 1 company. |
| What was the largest acquisition by Nanjing Pharmaceutical? | None of the M&A deals Nanjing Pharmaceutical has completed have disclosed valuations. |
| What companies Nanjing Pharmaceutical acquired? | Nanjing Pharmaceutical acquired Suzhou Tianqing Xingwei Pharmaceutical. |
| In how many companies Nanjing Pharmaceutical has invested to date? | As of September 2026, Nanjing Pharmaceutical has invested in 1 company. |
| In what companies Nanjing Pharmaceutical invested in? | Nanjing Pharmaceutical invested in WANHU HEALTH. |
See public comps similar to Nanjing Pharmaceutical
Lists including Nanjing Pharmaceutical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




